Ezetimibe is a Small Molecule owned by Merck & Co, and is involved in 74 clinical trials, of which 72 were completed, and 2 are ongoing.
Ezetimibe inhibits sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols. Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.
The revenue for Ezetimibe is expected to reach a total of $4.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ezetimibe NPV Report.
Ezetimibe is currently owned by Merck & Co. Organon is the other company associated in development or marketing of Ezetimibe.
Ezetimibe (Zetia/ Ezetrol/ Zient/ Viemm/ Absorcol) is a lipid-lowering agent. Ezetrol selectively inhibit the intestinal absorption of cholesterol and related plant sterols. It is formulated as tablets for oral route of administration. It is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B) and non high-density lipoprotein cholesterol (non-HDL-C) in pat ients with primary (heterozygous familial and non- familial) hyperlipidemia as a monotherapy, in combination with a 3- hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia, in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL- C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia, in combination with atorvastatin or simvastatin is indica ted for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable, as adjunctive therapy to di et for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. It is used for the treatment of primary hypercholesterolaemia, homozygous familial hypercholesterolaemia (hofh) and it is indicated to reduce the risk of major cardiovascular events in patients with chronic kidney disease.
Organon is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It works in collaboration with pharmaceutical and biopharmaceutical companies to commercialize its products. Organon is headquartered in Jersey City, New Jersey, the US.
The company reported revenues of (US Dollars) US$6,304 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.5% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 42.1% in FY2020. In FY2021, the company recorded a net margin of 21.4%, compared to a net margin of 33.1% in FY2020. The company reported revenues of US$1,537 million for the third quarter ended September 2022, a decrease of 3% over the previous quarter.
Quick View – Ezetimibe
|Highest Development Stage|